An Open-Label Study of DCCR Tablet in Patients With PWS

Stopped Study was never initiated; rather the duration of open-label study C602 (NCT03714373) was extended.

Conditions

• Prader-Willi Syndrome

Interventions

• DRUG: DCCR

Sponsor

Soleno Therapeutics, Inc.